Facebook
Twitter
LinkedIn
Forward| Organogenesis - Exhibitor | |
|---|---|
Organogenesis is a leading regenerative medicine company focused on empowering healing through the development, manufacturing and sale of products for the advanced wound care, and surgical and sports medicine markets. Our mission is to provide an integrated portfolio of healing solutions that improve lives while lowering the overall cost of health care. We are relentless in the pursuit of quality and innovations that make all the difference. Our advanced wound care products are designed for the treatment of chronic and acute wounds. We offer a comprehensive portfolio of regenerative medicine products capable of supporting patients from early in the wound healing process through to wound closure, regardless of wound type. PuraPly® Antimicrobial (PuraPly® AM) Wound Matrix is an FDA 510(k)-cleared Class II medical device indicated for the management of a variety of acute and chronic wound types, including partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, trauma wounds, draining wounds, and first- and second-degree burns. NuShield® is a more complete dehydrated placental allograft designed to protect and support healing in a variety of wound sizes and types. It is an easy-to-use, off-the-shelf product available in multiple sizes. Apligraf® is an FDA-approved, bioengineered living cell therapy indicated for the healing of venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs). Dermagraft® is an FDA-approved, bioengineered human dermal substitute indicated for the healing of diabetic foot ulcers (DFUs). Additional Information | |
